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Background/aim: The aim of this study is to scrutinize the effects of crocin on obesity and type-2 diabetes, with an approach that takes
oxidative stress and inflammatory parameters into account.
Materials and methods: The experimental obesity model was created by utilizing a 10-week-long high-fat diet (HFD). An experimental
type-2 diabetes model was created by injecting multiple low-dose streptozocin (STZ) injections into rats that were fed with the HFD.
The treatment groups were administered a daily crocin dose of 150 mg/kg for 6 weeks via gavage.
Results: Findings of the study demonstrated that crocin could be effective in relieving the symptoms of obesity and diabetes
(hyperinsulinemia, hyperleptinemia, insulin resistance, and weight gain). It was determined that crocin lowered the plasma TNF-α
and IL-1β levels and the pancreas tissue TNF-α and IFN-γ levels, which were increased due to diabetes, and reduced the inflammation
in diabetic rats. Similarly, it was found that oxidative stress, which increased due to the progress of diabetes, was reduced in crocin
treatment group.
Conclusion: Crocin could contribute to the development of phytotherapeutic approaches in the treatment of obesity, diabetes, and
diabesity (obesity-induced diabetes), which is promising as the abovementioned incidences have increased considerably in today’s
world.
Key words: Crocin, diabetes, obesity, high-fat diet, inflammation, oxidative stress

1. Introduction
Today obesity and diabetes are among the most widespread
social problems and are significant health problems both for
governments and for society at large. Studies demonstrate
that the frequency of obesity and diabetes (especially type2 diabetes) have increased rapidly throughout the world
(1–3).
Most individuals with type-2 diabetes display obesity
or adiposity, and hence it is possible to assert that these
two problems observed in society are interlinked. The
reason for this assertion is straightforward since both
conditions share the same characteristic, insulin resistance
(4–6). Increasing adipose tissue and increasing activity of
adipokines, which are secreted from tissues due to obesity,
stimulate insulin resistance both in peripheral tissues and
in the pancreas (6–8). Furthermore, the lipotoxicity that
is induced due to the increase in adipose tissue increases
the oxidative stress in the related tissues, thus contributing
to the development of insulin resistance (9,10).
Hyperglycemia develops over time as a result of insulin
resistance and accordingly oxidative stress increases due
* Correspondence: omerhazman@hotmail.com

to glucotoxicity and lipotoxicity. Pancreatic beta (β)-cell
dysfunction develops due to the increase in oxidative stress
and/or as a result of adipose tissue-induced inflammation,
and further β-cell damage could cause the development of
type-2 diabetes (11–13).
Today several natural antioxidants that reduce the
inflammation and oxidative stress induced by obesity
and type-2 diabetes are the subjects of debate about
their possible use in treatment and have increasingly
appeared as the focus of recent studies. Crocin is one of
these components, which is a natural carotenoid found
in saffron (Crocus sativus L.) and gardenia (Gardenia
jasminoides J.Ellis) flowers. It is a compound formed
by a disaccharide called gentiobiose and a dicarboxylic
acid called crocetin, which is soluble in water, and is in
diester form with high thermal stability (14–16). Studies
demonstrated that crocin could possess antioxidant (17),
antiplatelet (18), neuroprotective (19), antihyperlipidemic
(20,21), antidiabetic (22–24), and anticarcinogenic (25)
properties due to its pharmacological effects. However,
a literature review revealed no studies on the possible
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ways in which crocin affects obesity and type-2 diabetesinduced inflammation and oxidative stress. In this context,
it was concluded that by exhibiting the effects of crocin
on oxidative stress and inflammation in obesity and type-2
diabetes, this study might serve as a foundation for future
studies on the treatment of these diseases.
2. Materials and methods
2.1. Materials
In this study, tumor necrosis factor alpha (TNF-α),
interleukin (IL)-1β, IL-6, and interferon gamma (IFN-γ)
were purchased from e-Bioscience in Vienna, Austria. The
cytokine, leptin (BioVendor, Bratislava, Slovakia), insulin
(DRG-Diagnostic, Marburg, Germany), and total protein
(Fluka, St. Louis, MO, USA) levels were measured with an
ELISA device (ELx800, BioTek Inc., Winooski, VT, USA).
Total antioxidant status (TAS) and total oxidant status
(TOS), which are among the oxidative stress parameters,
were measured using kits (Rell Assay, Gaziantep, Turkey)
that work with spectrophotometric methods. The
streptozocin (STZ), crocin, and PBS were obtained from
Sigma Chemical Company (St. Louis, MO, USA). All other
chemicals used in the study were of the highest grade
available.
2.2. Animals and high-fat diet preparation
A total of 40 male Wistar albino rats were used in this study.
Rats were procured from the Afyon Kocatepe University
Experimental Animal Research and Application Center.
Rats were continuously cared for, fed, and provided
with water daily. The study was conducted at the Afyon
Kocatepe University Experimental Animal Research and
Application Center by providing 55%–60% humidity and
a 12:12-h light-dark cycle. All interventions on the animals
during the study process were conducted in compliance
with the permissions obtained from the Afyon Kocatepe
University Experimental Animal Local Ethics Committee,
Turkey (Approval Date/No: 2012/182).
A high-fat diet (HFD) was administered to all study
groups except for the control group to induce experimental
obesity and to induce insulin resistance, which is one of the
characteristics of type-2 diabetes. HFD implementation to
induce weight gain and insulin resistance was designed
in obese and diabetes study groups as follows: rat
food obtained from the feed plant was pulverized and
homogenized after adding 5% fatty soy and 5% eggs as
a source of protein, and 50% tallow as an energy source,
and then it was formed into a pellet and preserved in
deep-freeze. During the study HFD with 4930 cal/kg of
metabolic energy level was prepared fresh every week and
given to the animals 1 h after being removed from deepfreeze.
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2.3. Experimental design
HFD was administered to the rats for 10 weeks to induce
experimental obesity. At the end of this period, only the
rats in the HFD-administered obese group that displayed
hyperinsulinemia and hyperleptinemia in parallel with the
weight increase and insulin resistance were considered
obese.
A literature review on inducing an experimental type-2
diabetes model demonstrated that low-dose STZ injection
after HFD administration could successfully imitate type2 diabetes physiopathology (26,27). It was stated that two
doses of 30 mg/kg STZ injections administered a week
apart was the most ideal application (28). Thus, initially
insulin resistance was initiated in rats, which were planned
to be induced with experimental diabetes. Subsequently,
30 mg/kg doses of STZ dissolved in citrate buffer (pH 4.5)
were administered in the 3rd week (1 dose) and the 4th
week (1 dose) of the study using i.p. injection (28). One
week after the last injection (at the end of the 4th week),
glucose levels of the fasting rats were measured in a drop
of blood taken from the tail veins. Rats with a glucose level
of ≥300 mg/dL were accepted as suffering from type-2
diabetes.
Crocin administration was initiated to two groups: one
diabetic group after the induction of type-2 diabetes and
one obesity group that was only administered the HFD.
Crocin was prepared daily, just before its application to
rats. It was dissolved in physiological saline water for 6
weeks with a daily dose of 150 mg/kg (22) before being
administered to the experimental animals by gavage.
A total of 40 male Wistar albino rats weighing 200–250
g (mean: 230 g) were randomly divided into five groups
including 8 rats in all groups. The study groups were
designed as follows:
Group 1: Control group (Control): Composed of
healthy rats.
Group 2: Obesity group (Obesity): Composed of rats
that were fed with the HFD during the study.
Group 3: Obesity-treatment group (Obesity-Crocin):
Healthy rats that were fed with the HFD throughout the
study and were administered crocin for 6 weeks.
Group 4: Diabetes group (DM): Composed of rats that
were fed with a high-energy high-fat diet during the study
and were induced with experimental type-2 diabetes.
Group 5: Diabetes-treatment group (DM-Crocin):
Rats induced with type-2 diabetes that were treated with
crocin for 6 weeks.
The changes in the weights and fasting glucose levels of
rats were measured with an interval of 2 weeks during the
study. Prior to measurements, rats were left hungry for a
night. Fasting glucose levels were measured using a drop of
blood obtained from the tail vein by a glucometer (AccuChek Performa Nano, Roche, Mannheim, Germany). At
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the end of the 6-week-long crocin application (10th week of
the study), rats were anesthetized using ketamine (65 mg/
kg) and xylazine (7 mg/kg) to obtain the required blood
and tissue specimens for the analysis, and consequently
specimens were prepared for biochemical analyses.
Blood samples, which were used in analyses
containing plasma heparin, were transferred into tubes
and centrifuged (Hettich, Tuttlingen, Germany) for 10
min at 3000 rpm and 4 °C. Tissue homogenates used in
analyses were prepared as follows: 0.5 g of incised pancreas
tissue was transferred into a homogenizer (IKA T18, IKA,
Staufen, Germany) and 5 mL of PBS (pH 7.4) solution that
contained 8% protease inhibitor (Roche) was added and
homogenized. In all stages of the study, the maintenance of
a cold chain was ensured. Homogenates were centrifuged
for 10 min at 15,000 rpm and 4 °C. Plasma and pancreas
samples, which were prepared to be used in the analyses,
were stored at –80 °C until they were analyzed in the
laboratory.
2.4. Biochemical analysis
Pancreas and plasma TNF-α, IL-1β, IL-6, and IFN-γ levels;
plasma insulin levels; plasma leptin levels; and pancreas
tissue total protein levels were analyzed with an ELISA
device in compliance with the rat-specific kit protocols.
Oxidative stress parameters of TAS and TOS levels were
measured with kits running on the spectrophotometric
method (29,30). Resulting TAS and TOS data were used
to calculate the oxidative stress index (OSI = [(TOS /
TAS) × 100]). Furthermore, β-cell function (HOMA-β),
insulin resistance (HOMA-IR), and quantitative insulin
sensitivity check (QUICKI) indices for test groups were
calculated with the help of the formulas shown below,
using starvation insulin and glucose levels (31,32).

HOMA-β = [20 × fasting insulin levels (mU/L)] /
[fasting glucose levels (mmol/L) – 3.5]
HOMA-IR = [fasting insulin levels (mU/L) × fasting
glucose levels (mmol/L) / 22.5]
QUICKI = [1 / (log (fasting insulin μU / mL) + log
(fasting glucose mg / dL)]
The concentrations, which are related to the parameters
analyzed in pancreas tissue (TAS, TOS, TNF-α, IL-1β, IL6, IFN-γ), were divided into the final total protein levels
to obtain the results. Results were expressed in const./g
protein or const./mg protein.
2.5. Statistical analysis
All numerical results are expressed as mean ± standard
deviation of the mean for the indicated number of
experiments. Statistical significance was calculated with
the ANOVA test with the Duncan posttest and results were
considered significant at P < 0.05. Data were analyzed with
SPSS 18.0 (SPSS Inc., Chicago, IL, USA) for Windows.
3. Results
3.1. Weight change in the experimental groups during
the study
Once the data collected in the last week of the study (10th
week) were evaluated it was observed that average rat
weight in the HFD group was statistically different and was
heavier than in all the other groups (Table 1; Figure 1A).
The findings demonstrated that average rat weight in the
DM group and DM-Crocin group was significantly lower
than in the other groups. The comparison of the last week’s
data for the Obesity group and Obesity-Crocin group
displayed that average rat weight in the Obesity-Crocin
group was significantly lower than in the Obesity group.
However, there was no difference between the average rat

Table 1. Average weight gain observed in the experimental group during the study period.
Study groups
Control (g)

Obesity (g)

Obesity-Crocin (g)

DM (g)

DM-Crocin (g)

P

Week 0

237.3 ± 17.6

234.3 ± 23.1

239.8 ± 19.4

235.8 ± 26.2

239.1 ± 22.7

0.989

Week 2

262.6 ± 18.9

266.7 ± 20.7
300.4 ± 21.9

278.4 ± 19.3
325.3 ± 39.3

272.7 ± 28.4
251.6 ± 22.1

279.8 ± 24.7
298.4 ± 19.8

0.569
0.000

Week 4

276.3 ± 16.1

Week 6

290.1 ± 20.5 a

324.8 ± 29.1 b

328.8 ± 36.8 b

261.3 ± 23.2 a

286.4 ± 22.4 a

0.000

Week 8

305.0 ± 16.0

361.3 ± 21.5

321.8 ± 33.7

276.4 ± 35.3

279.6 ± 25.3

a

0.000

Week 10

323.3 ± 14.4 b

279.1 ± 24.5 a

0.000

a,b

a,b

b,c

c

387.8 ± 31.3 c

c

b

342.0 ± 28.6 b

a

a

280.0 ± 44.2 a

b,c

Values are mean ± standard deviation; n = 8.
a, b, c
: Different letters in the same line represent statistically significant differences (P < 0.05) among experimental groups. Obesity: The
group that was given only high-fat diet. DM: The group that was fed a high-fat diet throughout the study and in which type-2 diabetes
was generated. DM-Crocin: Diabetic group treated with crocin. Obesity-Crocin: Crocin was given for 6 weeks to rats that were given a
high-fat diet during the study.
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Figure 1. Antiobesity and antidiabetic effects of crocin. A) Antiobesity effect of crocin (the average weight gain observed in the
experimental group throughout the study period). B) Antidiabetic effect of crocin (change in the plasma glucose levels of the
experimental groups during the study period). Obesity: The group that was given only high-fat diet. DM: The group that was fed
a high-fat diet throughout the study and in which type-2 diabetes was generated. DM-Crocin: Diabetic group treated with crocin.
Obesity-Crocin: Crocin was given for 6 weeks to rats that were given a high-fat diet during the study.

weights of the DM group and DM-Crocin group (Table 1;
Figure 1A).
3.2. Blood glucose levels determined during the study
The data for the 4th week of the study were analyzed and
the analysis revealed that fasting blood glucose levels
for groups with induced diabetes (DM and DM-Crocin)
were statistically different and quite higher than those of
the other groups (Table 2; Figure 1B). Correspondingly,
HOMA-β values, which were calculated as an expression
of pancreatic β-cell function, established that HOMA-β
index data (Table 3) for the DM groups were very low. In
the comparison between the Control group and Obesity
group, no statistical difference was observed for the first
8 weeks of the study. Nevertheless, a slow and slight
increase in the blood glucose levels of the Obesity group
was evident for each passing week after week 8. Once the
10th week’s fasting glucose levels were examined, it was
observed that the Obesity group’s average fasting blood
glucose levels were higher with a statistically significant
difference as compared to Control group findings (Table
2). The Obesity-Crocin group’s blood glucose levels did
not change significantly due to crocin administration to
HFD-administered rats in comparison to the HFD group.
These findings demonstrate that studies with longer
durations are required to determine the effects of crocin
on fasting glucose levels in obesity-induced rats with HFD,
and through such studies it would be possible to obtain
more concrete findings.
3.3. Results of the biochemical parameters analyzed in
plasma
The findings indicated that Obesity group insulin levels
were increased, specifying the case of hyperinsulinemia.
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However, data obtained from the comparison of the DM
and Obesity-Crocin groups showed that crocin treatment
in diabetic rats did not affect the insulin levels (Table 3).
Comparison between the Obesity group and other groups
demonstrated that the HOMA-IR index findings were
highest in Obesity group rats, while QUICKI findings were
the lowest. Crocin decreased insulin resistance for the
Obesity group that was treated with crocin, yet it did not
reduce insulin resistance in the diabetic group. Another
characteristic feature observed in obesity and type-2
diabetes is the development of hyperleptinemia. In this
study, it could clearly be observed that hyperleptinemia
developed in the Obesity group (Table 3). As the effect of
crocin on Obesity and diabetic groups was scrutinized, it
was observed that crocin did not significantly affect the
leptin levels. However, crocin treatment increased insulin
sensitivity (QUICKI) both in the Obesity-Crocin group
(with respect to the Obesity group) and the DM-Crocin
group (with respect to the DM group).
3.4. Plasma cytokine and oxidative stress levels
The findings based on IL-6 levels indicate that there was
no statistically significant difference between the groups.
However, when the TNF-α levels were analyzed, significant
differences between the TNF-α levels of the groups were
recognized. Data for the DM group demonstrated that
there was a significant difference between the DM group
and both the Control group and Obesity group based on
the increase in TNF-α levels. TNF-α level for treatment
groups showed that the 6-week-long crocin treatment
statistically significantly lowered the TNF-α levels, which
had increased to levels of 79.72 ± 17.88 pg/mL due to type2 diabetes. However, this therapeutic effect of crocin was
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Table 2. Change in glucose levels in study groups during the study.
Study groups
Control
(mg/dL)

Obesity
(mg/dL)

Obesity-Crocin
(mg/dL)

DM
(mg/dL)

DM-Crocin
(mg/dL)

P

Week 0

103.0 ± 9.6

104.1 ± 9.1

100.3 ± 8.6

105.1 ± 8.0

102.0 ± 9.5

0.871

Week 2

106.4 ± 4.6

108.4 ± 6.6

111.8 ± 8.7

113.8 ± 9.3

112.7 ± 5.2

0.280

Week 4

104.8 ± 8.8 a

113.3 ± 5.9 a

119.6 ± 8.1 a

376.6 ± 53.8 b

357.0 ± 44.5 b

0.000

Week 6

105.3 ± 6.5 a

117.4 ± 13.4 a

129.4 ± 10.3 a

358.4 ± 55.4 c

303.7 ± 43.3 b

0.000

Week 8

105.7 ± 7.1 a

132.6 ± 15.4 a

127.3 ± 12.0 a

336.3 ± 55.3 c

272.6 ± 41.8 b

0.000

Week 10

102.6 ± 11.2

144.8 ± 15.8

125.6 ± 10.6

330.4 ± 46.6

232.7 ± 33.7

0.000

a

b

a,b

d

c

Values are mean ± standard deviation; n = 8.
a, b, c
: Different letters in the same line represent statistically significant differences (P < 0.05) among experimental groups. Obesity: The
group that was given only high-fat diet. DM: The group that was fed a high-fat diet throughout the study and in which type-2 diabetes
was generated. DM-Crocin: Diabetic group treated with crocin. Obesity-Crocin: Crocin was given for 6 weeks to rats that were given a
high-fat diet during the study.

Table 3. Plasma levels of biochemical, inflammatory, and oxidative stress markers.
Study groups
Control

Obesity

Obesity-Crocin

DM

DM-Crocin

P

Insulin (µg/L)

1.58 ± 0.26 b

2.11 ± 0.17 c

1.74 ± 0.25 b

0.42 ± 0.03 a

0.48 ± 0.07 a

0.000

Leptin (pg/mL)

276.0 ± 82.3 a

632.1 ± 149.9 c,d

742.9 ± 169.1 d

530.1 ± 114.3 b,c

456.2 ± 108.3 b

0.000

HOMA-β

346.4 ± 113.1

218.1 ± 51.8

230.6 ± 36.7

13.3 ± 3.5

a

24.2 ± 5.9

0.000

HOMA-IR

9.2 ± 1.6 b

7.8 ± 0.9 a,b

6.5 ± 1.7 a

QUICKI

0.2808 ± 0.0029

IL-6 (pg/mL)

31.9 ± 2.6

TNF-α (pg/mL)

c

b

17.4 ± 2.0 d
c

12.5 ± 2.5 c

0.2602 ± 0.0013

a

33.2 ± 2.2

74.3 ± 8.9

93.8 ± 10.5

IFN-γ (pg/mL)

94.2 ± 4.3

a

112.2 ± 13.1

IL-1β (pg/mL)

63.4 ± 16.8 a

91.7 ± 12.9 b

TAS (mmol Trolox equiv./L)

1.60 ± 0.09

1.87 ± 0.27

TOS (µmol H2O2 equiv./L)

4.63 ± 1.13 a

OSI [(TOS/TAS) × 100]

288.0 ± 65.3

91.4 ± 16.6

b

b

362.5 ± 107.2

0.2856 ± 0.0017

c

a

0.000

0.2936 ± 0.0034
32.1 ± 3.5

d

0.000
0.319

136.6 ± 16.8

c

79.7 ± 17.9

119.8 ± 17.9

b

124.9 ± 13.4

114.3 ± 13.8 c

113.7 ± 16.1 c

89.1 ± 19.9 b

0.000

1.69 ± 0.23

1.16 ± 0.20

1.71 ± 0.29

0.000

b
b

b

9.29 ± 1.84 c
a, b

b

35.6 ± 3.2

111.1 ± 14.1

b

6.72 ± 1.85 b
a

0.2706 ± 0.0024
30.3 ± 8.7

a

b

b

528.3 ± 113.6

a

10.25 ± 2.56 c
b

915.8 ± 345.7

c

a, b
b

b

0.000
0.002

5.32 ± 0.87 a,b

0.000

314.7 ± 62.2

0.000

a

Values are mean ± standard deviation; n = 8.
a, b, c
: Different letters in the same line represent statistically significant differences (P < 0.05) among experimental groups. Obesity: The
group that was given only high-fat diet. DM: The group that was fed a high-fat diet throughout the study and in which type-2 diabetes
was generated. DM-Crocin: Diabetic group treated with crocin. Obesity-Crocin: Crocin was given for 6 weeks to rats that were given a
high-fat diet during the study.

not observed in the Obesity group designed as the obese
group (Table 3).
The comparison of IFN-γ levels for the Control group
with the Obesity and DM groups revealed that both
Obesity and DM group IFN-γ levels showed statistically
significant differences and were higher than in the control

group. However, the outcomes demonstrated that crocin
treatment did not affect the IFN-γ levels in the Obesity
or the DM group (Table 3). There was an increase in IL1β levels for the DM and Obesity groups in comparison
to the control group. IL-1β levels for treatment groups
were analyzed and it was observed that crocin treatment
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Table 4. Findings on pancreas tissue oxidative stress and inflammatory parameters.
Study groups
Control

Obesity

Obesity-Crocin

DM

45.9 ± 2.4

b

41.5 ± 7.7

a,b

DM-Crocin

P

44.0 ± 6.9

a,b

38.3 ± 4.6

a

54.3 ± 4.0

c

55.3 ± 6.8

c

0.127

65.6 ± 3.9

d

45.9 ± 5.9

b

0.000
0.000

IL-6 (pg/mg protein)

42.6 ± 3.2

a,b

TNF-α (pg/mg protein)

35.8 ± 4.1

a

IFN-γ (pg/mg protein)

40.3 ± 3.3 a

44.5 ± 5.2 a

44.3 ± 3.8 a

53.4 ± 4.6 b

40.0 ± 4.0 a

IL-1β (pg/mg protein)

49.9 ± 1.3

49.7 ± 3.1

52.0 ± 2.6

56.4 ± 4.7

54.6 ± 3.7

TAS (mmol Trolox equiv./g protein)

0.59 ± 0.08

0.65 ± 0.13

0.61 ± 0.13

0.73 ± 0.13

0.61 ± 0.19

TOS (µmol H2O2 equiv./g protein)

3.38 ± 0.56 a

4.16 ± 0.44 b

4.06 ± 0.42 b

4.70 ± 0.32 c

3.67 ± 0.41 a,b

0.000

OSI [(TOS/TAS) × 100]

595.1 ± 163.2

670.1 ± 186.8

686.9 ± 149.7

662.7 ± 156.8

651.5 ± 183.7

0.775

a

a

a,b

c

b,c

0.002
0.327

Values are mean ± standard deviation; n = 8.
a, b, c
: Different letters in the same line represent statistically significant differences (P < 0.05) among experimental groups. Obesity: The
group that was given only high-fat diet. DM: The group that was fed a high-fat diet throughout the study and in which type-2 diabetes
was generated. DM-Crocin: Diabetic group treated with crocin. Obesity-Crocin: Crocin was given for 6 weeks to rats that were given a
high-fat diet during the study.

decreased the IL-1β levels that were previously increased
due to type-2 diabetes. However, this therapeutic effect
was not observed in the Obesity-Crocin group.
Examination of DM group findings demonstrated that
TAS levels decreased in comparison to both Control and
Obesity group data. Inspection of TAS levels in treatment
groups revealed that crocin significantly increased the
TAS levels, which were decreased due to the occurrence of
diabetes. However, comparison between TAS levels of the
Obesity and Obesity-Crocin groups showed that there was
no statistically significant difference. A review of TOS levels
revealed that the TOS levels of the Obesity and DM groups
were increased in comparison to the control group. An
inspection of the TOS levels in treatment groups revealed
that the 6-week-long crocin treatment decreased the TOS
levels in a statistically significant manner. However, this
therapeutic effect of crocin was not observed in HFD
groups, which were designed as the obese groups. A review
of OSI levels showed that the increase in OSI levels in the
DM group was significantly higher than the results for all
other groups. However, the oxidative stress-reducing effect
of crocin that was observed in the Diabetic group was not
repeated in Obesity groups.
3.5. Pancreas tissue cytokine and oxidative stress levels
Table 4 presents the levels of biochemical parameters
analyzed in the pancreas tissue of the study groups. The
comparison of TNF-α levels for Obesity and Control
groups indicated an increase in TNF-α levels in the HFD
group. On the other hand, the increase in TNF-α levels in
the DM group presented a statistically significant difference
and was higher than both the Control and Obesity group
findings. An inspection of the TNF-α levels in treatment
groups indicated that crocin treatment decreased the
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previously increased TNF-α levels due to the type-2
diabetes in a statistically significant manner, to levels of
45.9 ± 5.9 pg/mL. However, this therapeutic effect was not
observed in Obesity groups (Table 4). The examination of
IFN-γ levels for study groups revealed that IFN-γ levels of
the DM group were statistically different and higher than
in all other study groups. Furthermore, crocin treatment
did not affect the IL-1β levels in Obesity groups or diabetic
rats. The examination of TAS, TOS, and OSI data for study
groups revealed that Obesity group TOS levels were higher
than those of the control group (Table 4). DM group TOS
levels were higher than both Obesity and Control group
levels. Crocin treatment lowered TOS levels only in the
Diabetic group.
4. Discussion
This study investigated the possible effects of crocin
on obesity and type-2 diabetes. In addition, the study
attempted to determine the effects of crocin on obesity
induced by HFD application and define the possible
increase of oxidative stress and inflammation induced by
an experimental type-2 diabetes model.
4.1. Effects of crocin on obesity symptoms
Certain clinical symptoms that are characterized by
obesity, such as insulin resistance, hyperinsulinemia, and
hyperlipidemia, could be easily determined in individuals
in the first stages of obesity due to the increase of body
weight and glucose levels, although these individuals
experience no health problems (11,13,33,34). A literature
review revealed that several studies demonstrate an
increase in insulin and leptin levels due to weight
increase in obesity. In a study on the development of
obesity related to diet, hepatic lipidosis, hyperleptinemia,
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hyperinsulinemia, and insulin resistance were observed in
rats on a HFD, as well as weight increase (35). This study
and several parallel studies (36,37) demonstrated that
rats on HFDs developed differences in weight gains with
respect to the control group, and consequently symptoms
such as increase in insulin and leptin levels or development
of insulin resistance developed due to obesity. Similarly,
at the end of this study, the insulin, leptin, and starvation
glucose levels of the Obesity group had increased with
respect to the control group.
In this study, in compliance with the literature, the rats
that had an increase in body weight, leptin, and insulin
levels and had developed insulin resistance (36,38,39)
were administered a HFD and were accepted as obese.
The main reason behind the increase in insulin levels in
the Obesity group could be the secretion and release of
more insulin from the pancreas to tolerate the increasing
glucose levels, due to the insulin resistance developed
parallel to development of obesity. The leptin levels could
be due to the adipose tissue, which increased as a result
of HFD applications (11,40). In a study that examined
energy balance and leptin sensitivity in rats that developed
diet-induced obesity, leptin levels in parallel to weight
gains were found to be almost doubled in obese rats in
comparison to the control group (41).
It was determined that crocin treatment decreased
hyperleptinemia and hyperinsulinemia in the DM-Crocin
and Obesity-Crocin groups. The reason for the decrease
in secreted insulin levels in Obesity groups due to crocin
treatment could be the decrease in insulin secretion from
the pancreas as a result of crocin-increased sensitivity
of insulin (by reducing insulin resistance). Thus, it was
determined that at the end of the 6-week crocin treatment,
insulin resistance decreased while insulin sensitivity
increased in the Obesity-Crocin group. Decreased leptin
levels due to crocin could be explained by the negative
effect of crocin on the increase of body weight, since it has
been reported that leptin levels increased as a result of the
stimulation of adipogenesis together with the increase in
body weight due to HFD applications (11,42).
In summary, it is possible to assert that crocin could
contribute to the development of alternative treatment
protocols in the fight against obesity, since crocin
treatment, which was reported to reduce hyperleptinemia
and hyperinsulinemia in obesity, is considered to have
reduced insulin resistance (HOMA-IR) and body weight
increase in the Obesity group.
4.2. Effects of crocin on inflammation and oxidative
stress induced by obesity
In clinical studies and obesity models induced in
experimental animals using HFDs, it was determined
that obesity increased low-grade oxidative stress and
inflammation (11,33,43,44). The findings of this study

also pointed out that the administered fatty diet increased
oxidative stress and inflammation levels in the Obesity
group. It could be stated that inflammation occurred in
plasma due to the increase in the levels of TNF-α, IL-1β,
and IFN-γ and in pancreas tissue due to the increase in
the levels of TNF-α and IFN-γ (Tables 3 and 4). One of the
rare studies on the effects of crocin on obesity reported that
hyperlipidemia was induced by fatty diet implementation
and crocin reduced the serum triglyceride, total cholesterol,
ALP, AST, MDA, GPx, and GSH levels increased by the
HFD application (21). However, this study, in contradiction
with the findings of the above study, determined that crocin
treatment did not affect oxidative stress parameters (TASTOS and OSI) in plasma or pancreas tissue in the Obesity
group (Tables 3 and 4). Relatedly, it was determined that
crocin did not affect inflammation in plasma or pancreas
tissue, which was increased as a result of obesity. The
reason for the nonprevalence of the antiinflammatory (19)
and antioxidant (17,21) efficiency of crocin noted in the
literature for obese rats could be related to the application
length, methods (gavage or i.p), and the dose of crocin
given to obese rats. The literature review demonstrated
that most of the crocin is found in feces or in intestinal
content 24 h after oral administration. It was reported
that crocetin derived from crocin was found in plasma
in low concentrations (44). The reason for that could be
summarized as the break-up of the crocin into crocetin in
the small intestine 2 h after oral administration (45). Thus,
it could be stated that the determined effects of the crocin
in this study were in fact due to crocetin (46).
4.3. Antidiabetic efficiency of crocin in type-2 diabetes
HFD is usually not used in studies that aim to determine
the effects of crocin on diabetes (22–24); contrarily these
studies were conducted using high-dose STZ/alloxan
injection. It was stated in the literature that high-dose
STZ injections that were administered in experimental
animals without insulin resistance formation induced an
experimental type-1 diabetes model (26–28). In this study,
rats were initially administered HFD followed by low-dose
STZ injection to simulate type-2 diabetes physiopathology.
The findings demonstrated that leptin levels in the
DM group were very high, while insulin and HOMA-β
levels decreased (Table 3). These findings indicated that
leptin secretion from the adipose tissue was stimulated
by HFD application in diabetic rats, and with the STZ
injection β-cell dysfunction was induced. Crocin did not
affect insulin, leptin, HOMA-β, and HOMA-IR levels
when the crocin treatment was administered to diabetic
rats; however, it decreased glucose levels in comparison
to the DM group (Figure 1B). Certain findings among
these differ from the findings in the literature. In a
study examining STZ-induced diabetes (24) it was
determined that crocin administered to diabetic rats using
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intraperitoneal injections in daily doses of 50 and 100 mg/
kg lowered insulin levels and insulin resistance. On the
contrary, in this study, insulin levels and insulin resistance
did not change as a result of crocin treatment. The reason
for different postcrocin treatment results in diabetic rats
could be explained by the difference between experimental
diabetes models in different studies or between the
application methods or the doses of crocin administration.
For instance, in a study (24) on STZ-induced diabetes, a
type-1 diabetes model was induced with a high dose (90
mg/kg) STZ injection without HFD application (without
inducing insulin resistance). Hence, in this study a type2 diabetes model was created. Different experimental
diabetes models could yield different results even though
they use the same treatment agent such as crocin.
This study determined that crocin increased insulin
sensitivity (QUICKI) in diabetic rats although it had no
effects on insulin levels and insulin resistance. Conceivably,
this could be the reason why crocin decreased the glucose
levels in diabetic rats without affecting the insulin levels
and insulin resistance. The fact that crocin lowered glucose
levels without affecting insulin and insulin resistance
suggested that crocin might have suppressed hepatic
glucose production. However, further studies are required
to verify this.
4.4. Antiinflammatory and antioxidant efficiency of
crocin in type-2 diabetes
With the progress of type-2 diabetes, lipotoxicity and
glucotoxicity induced in patients debilitate the antioxidant
system and the oxidative stress increases. Oxidative
stress causes an increase in inflammation, especially by
stimulating the production of cytokines (8,11,47,48).
Thus, increased oxidative stress and inflammation
with diabetes play a significant role both in the further
progress of diabetes and the development of other diabetic
complications (7,49). This study determined that crocin
decreased plasma and pancreas oxidative stress levels.
These findings were in parallel with other studies cited in
the literature. It has been reported that this antioxidant
effect of crocin was due to its decreasing effect on advanced
glycation end products formation via the reduction in
glucose levels, suppression of lipid peroxidation, and its
support for the antioxidant system (23,24).
Although there are studies in the literature that
attempted to determine the effect of crocin on oxidative
stress, there are none that scrutinized the effects of crocin
on diabetes-induced inflammation. In this respect, the
findings of this study would contribute to explaining
the effects of crocin on inflammation developed due to
diabetes. The antiinflammatory efficiency of crocin was
significant when its effects on inflammation developed in
the diabetic group were examined. Thus, it was determined
that plasma TNF-α and IL-1β and pancreas tissue TNF-α
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and IFN-γ levels, which were increased due to diabetes
(Tables 3 and 4), were reduced by crocin. Several studies
demonstrated that a diabetes-induced increase in
inflammation activated apoptotic signal paths, causing an
increase in β-cell dysfunction and damage. Crocin, due
to its antiinflammatory efficiency as mentioned, could
be effective in reducing the pancreatic β-cell damage.
Accordingly, in a study conducted in a microglial cell
line with inflammation, crocin decreased cytokine
release and suppressed NF-κB activation (50). Another
study demonstrated that, due to its antiinflammatory
characteristics, crocin could activate/inhibit one or several
metabolic pathways. It was reported that crocin, due to
its antiinflammatory effects, inhibited the cytochrome-c
that activates caspase-3 by splitting off the mitochondria,
and thus decreased neuronal cell damage in the neuronal
PC-12 cell path (19). This study also suggested that crocin
inhibiting/activating internal and external apoptotic
stimulations, especially in β cells, could be significant in
diabetic treatment. However, further studies are needed to
determine concrete results.
This study further scrutinized the effects of crocin
on the increased inflammation and oxidative stress in
rats, parallel to the progress of experimental obesity
and type-2 diabetes. It was determined that crocin had
limited effects on obesity-induced oxidative stress and
inflammation. However, it was specified that crocin
had antioxidative and antiinflammatory effects against
oxidative stress and inflammation that has increased as a
result of glucotoxicity and lipotoxicity in type-2 diabetes.
While low-grade oxidative stress and inflammation are
induced as a result of the development of obesity, higher
levels of oxidative stress and inflammation are observed
due to the development of diabetes. In the present study,
antiinflammatory and antioxidant effects of crocin on
diabetic rats were observed more clearly than in obese rats.
This could be due to the possibility that crocin might not
be very effective in pathologies with low levels of oxidative
stress and inflammation. Furthermore, an analysis of the
data presented in Table 3 would demonstrate that IL-1β
and TOS levels increased when crocin was applied to the
obesity group. These findings might be due to the possible
increasing effects of crocin on inflammation and oxidative
stress. However, the data available in the present study are
limited for drawing concrete conclusions.
When the significant roles of oxidative stress
and inflammation on the development of diabetic
complications (48) and insulin resistance (11,33) are
considered, the reducing effect of crocin on oxidative
stress and inflammation could be beneficial in diabetic
treatment. In addition, it was determined that crocin
helped reduce the symptoms of obesity. Concerning its
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antiobesity effects, crocin could contribute to developing
alternative treatment protocols in the fight against obesity.
However, for crocin to be defined as an antiobesity agent,
further research is necessary to investigate its effects on
adipogenesis and energy metabolism.
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